|
|
| (31 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| | | |valign=top| |
| {{Reteplase}}
| | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| {{CMG}}; {{AE}} {{AZ}}
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| '''''For patient information, click <u>[[Reteplase (patient information)|here]]'''''</u>.
| | |- |
| {{SB}} Retavase<sup>®</sup>
| | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| ==Overview==
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| '''Reteplase''' (trade names '''Retavase''', '''Rapilysin''') is a [[thrombolytic drug]], used to treat [[myocardial infarction|heart attacks]] by breaking up the [[clot]]s that cause them.
| | |} |
| | |
| Reteplase is a recombinant non-glycosylated form of human [[tissue plasminogen activator]], which has been modified to contain 357 of the 527 [[amino acid]]s of the original [[protein]]. It is produced in the [[bacterium]] [[Escherichia coli]].{{citation needed|date=December 2013}}
| |
| | |
| Reteplase is similar to recombinant human tissue plasminogen activator ([[alteplase]]), but the modifications give reteplase a longer [[half-life]] of 13–16 minutes. Reteplase also binds [[fibrin]] with lower affinity than alteplase, improving its ability to penetrate into clots.
| |
| | |
| Reteplase was approved by the [[Food and Drug Administration]] in 1996.
| |
| | |
| ==Category==
| |
| [[Thrombolytics]], tissue plasminogen activators.
| |
| ==FDA Package Insert==
| |
| ===Retavase<sup>®</sup>===
| |
| ''' [[Reteplase indications and usage|Indications and Usage]]'''
| |
| '''| [[Reteplase dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Reteplase dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Reteplase contraindications|Contraindications]]'''
| |
| '''| [[Reteplase warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Reteplase adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Reteplase drug interactions|Drug Interactions]]'''
| |
| '''| [[Reteplase use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Reteplase overdosage|Overdosage]]'''
| |
| '''| [[Reteplase description|Description]]'''
| |
| '''| [[Reteplase clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Reteplase nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Reteplase clinical studies|Clinical Studies]]'''
| |
| '''| [[Reteplase how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Reteplase patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Reteplase labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| Retavase® is a recombinant [[plasminogen activator]] which catalyzes the cleavage of endogenous [[plasminogen]] to generate [[plasmin]]. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.1,2In a controlled trial, 36 of 56 patients treated for an acute myocardial infarction (AMI) had a decrease in [[fibrinogen]] levels to below 100 mg/dL by 2 hours following the administration of Retavase® as a double-bolus intravenous injection (10 + 10 unit) in which 10 units (17.4 mg) was followed 30 minutes later by a second bolus of 10 units (17.4 mg).3 The mean fibrinogen level returned to the baseline value by 48 hours.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = |accessdate = }}</ref>
| |
| | |
| ==References== | |
| | |
| {{Reflist|2}}
| |
| [[Category: cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |